Efficiency of Edaravone in Treatment of Amyotrophic Lateral Sclerosis
Phase 4
- Conditions
- Health Condition 1: G122- Motor neuron disease
- Registration Number
- CTRI/2019/11/021838
- Lead Sponsor
- ARMED FORCES MEDICAL RESEARCH COMMITY
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients, who are more than 18 years of age and are diagnosed to have possible, probable or definite ALS as per the El Escorial Criteria 2014, will be included.
Exclusion Criteria
Patients will be excluded if they have liver or kidney disorder (eGFR < 50ml/min), malignancy, uncontrolled hypertension, or any structural brain or spinal cord lesion
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (i) To find out the efficacy of Edaravone in all patients of amyotrophic lateral sclerosis in improvement with respect todefined parameters at the end of 6 months. <br/ ><br> <br/ ><br>(ii) To find out the efficacy of Edaravone in a subset of serving personnel having ALS, military service being a risk factor for ALS <br/ ><br>Timepoint: 6 and 12 months
- Secondary Outcome Measures
Name Time Method To study the SFEMG parameter measures in ALS patients and correlate them with their clinical evaluationTimepoint: 6 and 12 months